AbbVie-Allergan complete, but critics continue to raise anti-competitive concerns
The Abbvie-Allergan mega-merger may now be complete, but its critics haven’t had their last say.
In a 7-page letter to the Federal Trade Commission, California Attorney General Xavier Becerra called into question the remedies the federal agency imposed to solve the anti-trust concerns intrinsic in the $63 billion deal.
He said the agency did not follow its own “best practices” when it comes to the merger. Yet even these practices — now commonplace in some form or another — have consistently failed to curtail anti-competitive and price-raising potential, Becerra argued, and should be studied thoroughly in an effort to come up with new fixes.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.